SPG11 and amyotrophic lateral sclerosis: As we have already shown for SPTLC1 related ALS5, this notion has important therapeutic implication in our SPTLC2-ALS patients also, arguing against serine supplementation in SPTLC2-ALS which may drive the pathogenesis further.